|
Friday, January 20, 2023, San Francisco, California, 6:00 PM – 7:30 PM Pacific Time (9:00 PM – 10:30 PM Eastern Time)
Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Hepatobiliary CancersPart 3 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Gastrointestinal Cancers Symposium
Location
San Francisco Marriott Marquis 780 Mission Street San Francisco, CA 94103 Hotel Phone: (415) 896-1600 Program Schedule — Pacific Time 5:30 PM – 6:00 PM — Registration and Dinner 6:00 PM – 7:30 PM — Educational Meeting Meeting Room Golden Gate Ballroom — Salon A (B2 Level) This event will also be webcast live. Please see Registration tab for details. Faculty
Richard S Finn, MD Professor, Department of Medicine, Division of Hematology/Oncology David Geffen School of Medicine at UCLA Director, Signal Transduction and Therapeutics Program Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California Lipika Goyal, MD, MPhil Director of Gastrointestinal Oncology Stanford Cancer Center Associate Professor Stanford University School of Medicine Palo Alto, California Professor Arndt Vogel, MD Managing Senior Consultant Department of Gastroenterology, Hepatology and Endocrinology Hannover Medical School Hannover, Germany Moderator Robin K (Katie) Kelley, MD Professor of Clinical Medicine Division of Hematology/Oncology Helen Diller Family Comprehensive Cancer Center University of California, San Francisco (UCSF) San Francisco, California This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation, and Merck.
Program Schedule — Pacific Time 5:30 PM – 6:00 PM — Registration and Dinner Buffet 6:00 PM – 7:30 PM — Educational Meeting MODULE 1: First-Line Treatment for Advanced Hepatocellular Carcinoma (HCC) — Dr Finn
MODULE 2: Selection and Sequencing of Therapies for Relapsed/Refractory HCC — Dr Kelley
MODULE 3: Current and Future Role of Immunotherapy in the Treatment of Advanced Biliary Tract Cancers (BTCs) — Prof Vogel
MODULE 4: Integration of Targeted Therapy into the Management of Advanced BTCs — Dr Goyal
Target Audience
CME Credit Form FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Finn — Advisory Committee: CStone Pharmaceuticals; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, Lilly, Merck, Pfizer Inc; Contracted Research (to Institution): Adaptimmune, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Hengrui Therapeutics Inc; Speaker’s Bureau: Genentech, a member of the Roche Group. Dr Goyal — Advisory Board and Consulting Agreements: Alentis Therapeutics AG, Black Diamond Therapeutics Inc, Exelixis Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Incyte Corporation, Kinnate Biopharma, Merck, QED Therapeutics, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Surface Oncology, Taiho Oncology Inc, TransThera Biosciences, Tyra Biosciences; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Prof Vogel — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Böhringer Mannheim, Bristol-Myers Squibb Company, BTG, Daiichi Sankyo Inc, Eisai Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation; Speaker: Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Böhringer Mannheim, Bristol-Myers Squibb Company, BTG, Daiichi Sankyo Inc, Eisai Inc, GlaxoSmithKline, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jiangsu Hengrui Medicine Co Ltd, Merck Sharp & Dohme LLC, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation.MODERATOR — Robin K (Katie) Kelley, MD – Advisory Board: Kinnate Biopharma; Advisory Board or Steering Committee (to Institution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck; Advisory Committee: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Kinnate Biopharma, Merck; Research Funding to Institution: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Partner Therapeutics, QED Therapeutics, Relay Therapeutics, Surface Oncology, Taiho Oncology Inc; Uncompensated Service on IDMC: Genentech, a member of the Roche Group, Merck. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation, and Merck. San Francisco Marriott Marquis
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers. IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this in-person event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 5:30 PM PST on Friday, January 20th. If you are interested in attending, please visit our registration desk located outside the Gold Gate Ballroom – Salon A (B2 Level) of the San Francisco Marriott Marquis hotel (780 Mission Street) within walking distance of the Moscone Convention Center (2 street blocks).
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. NOTICE: Registration for this event is independent of registration for the 2023 ASCO GI Symposium. LIVE WEBCAST registration for all professionals
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not official events of the 2023 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation. |